<p>在過去三個月中，13 位分析師對 Zimmer Biomet Holdings（紐約證券交易所代碼：ZBH）發佈了從看漲到看跌的多樣化評級。</p>
<p>下表提供了他們最近評級的簡要概覽，展示了過去 30 天情緒的變化，並與前幾個月進行了比較。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">2</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
<p>分析師通過對 12 個月價格目標的評估提供了更深入的見解，揭示了平均目標為 101.08 美元，最高預估為 120.00 美元，最低預估為 86.00 美元。目前的平均價格目標較之前的平均價格目標下降了 3.94%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769626848_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="價格目標圖表" width="700" height="500" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769626848_0.png"/></p>
<h2>理解分析師評級：全面解析</h2>
<p>對近期分析師行動的深入分析揭示了金融專家對 Zimmer Biomet Holdings 的看法。以下總結概述了關鍵分析師、他們的最新評估以及對評級和價格目標的調整。</p>
<table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>下調</td>
<td>賣出</td>
<td>$86.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>上調</td>
<td>市場表現</td>
<td>$99.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>維持</td>
<td>買入</td>
<td>$112.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>上調</td>
<td>超越市場</td>
<td>$120.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>下調</td>
<td>中性</td>
<td>$100.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>下調</td>
<td>中性</td>
<td>$94.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Caitlin Roberts</td>
<td>Canaccord Genuity</td>
<td>下調</td>
<td>持有</td>
<td>$93.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>下調</td>
<td>賣出</td>
<td>$88.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>下調</td>
<td>超越市場</td>
<td>$101.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>下調</td>
<td>低配</td>
<td>$104.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>下調</td>
<td>中性</td>
<td>$100.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>下調</td>
<td>低配</td>
<td>$105.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>下調</td>
<td>買入</td>
<td>$112.00</td>
<td>$122.00</td>
</tr>
</tbody>
</table>
<h3>關鍵見解：</h3>
<ul>
<li><strong>採取的行動：</strong> 分析師根據市場動態和公司表現更新他們的建議。無論是'維持'、'上調'還是'下調'，都表明他們對 Zimmer Biomet Holdings 近期發展的反應。這為分析師對公司當前狀態的看法提供了見解。</li>
<li><strong>評級：</strong> 分析師提供的定性見解揭示了股票表現，從'超越市場'到'低於市場'。這些評級傳達了對 Zimmer Biomet Holdings 相對於更廣泛市場的表現預期。</li>
<li><strong>價格目標：</strong> 分析師設定價格目標作為對股票未來價值的估計。比較當前和之前的價格目標提供了分析師預期隨時間變化的見解。這些信息對尋求瞭解股票潛在未來表現的投資者來説非常有價值。</li>
</ul>
<p>將這些分析師評估與相關財務指標結合分析，可以全面瞭解 Zimmer Biomet Holdings 的市場地位。保持信息靈通，並在我們的評級表的幫助下做出數據驅動的決策。</p>
<p>隨時瞭解 Zimmer Biomet Holdings 的分析師評級。</p>
<h2>發現 Zimmer Biomet Holdings：更深入的瞭解</h2>
<p>Zimmer Biomet 設計、製造和銷售骨科重建植入物，以及骨科手術所需的供應和手術設備。通過在 2003 年收購 Centerpulse 和在 2015 年收購 Biomet，Zimmer 在美國、歐洲和日本的重建市場中佔據領先份額。大約三分之二的總收入來自大型關節的銷售；另外四分之一來自四肢、創傷、運動醫學和相關手術產品。該公司於 2022 年剝離了其牙科和脊柱業務。</p>
<h3>Zimmer Biomet Holdings：深入財務分析</h3>
<p><strong>市值視角：</strong> 該公司的市值低於行業平均水平，表明其相較於同行規模較小。這種定位可能受到感知增長潛力或運營規模等因素的影響。</p>
<p><strong>收入增長：</strong> Zimmer Biomet Holdings 在 2023 年第三季度表現出積極的結果。截至 2025 年 9 月 30 日，該公司實現了約 <strong>9.71%</strong> 的穩健收入增長率。這表明公司的營業收入顯著增加。與行業同行相比，該公司的增長率低於醫療保健行業的平均水平。</p>
<p><strong>淨利潤率：</strong> 該公司的淨利潤率表現突出，超過行業平均水平。憑藉 <strong>11.54%</strong> 的淨利潤率，該公司展示了強大的盈利能力和有效的成本控制。</p>
<p><strong>股本回報率（ROE）：</strong> 該公司的 ROE 低於行業基準，表明在有效利用股本方面可能存在困難。ROE 為 <strong>1.83%</strong>，公司可能需要解決為股東創造滿意回報的挑戰。</p>
<p><strong>資產回報率（ROA）：</strong> Zimmer Biomet Holdings 的 ROA 低於行業標準，表明在有效利用資產方面可能存在困難。ROA 為 <strong>1.0%</strong>，公司可能面臨從其資產中提供滿意回報的挑戰。</p>
<p><strong>債務管理：</strong> Zimmer Biomet Holdings 的債務與股本比率低於平均水平，為 <strong>0.64</strong>，採取了謹慎的財務策略，表明其在債務管理方面採取了平衡的方法。</p>
<h2>分析師評級基礎知識</h2>
<p>Benzinga 跟蹤 150 家分析師公司並報告它們的股票預期。分析師通常通過預測公司未來的盈利能力，通常是接下來的五年，以及該公司的收入來源的風險性或可預測性，來得出結論。</p>
<p>分析師參加公司電話會議和會議，研究公司財務報表，並與內部人士溝通，以發佈他們對股票的評級。分析師通常每季度對每隻股票進行一次評級，或者在公司有重大更新時進行評級。</p>
<p>一些分析師發佈他們對增長預期、收益和收入等指標的預測，以提供額外的評級指導。在使用分析師評級時，重要的是要記住，股票和行業分析師也是人，他們只是向投資者提供自己的意見。</p>
<p>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</p>

<p>最近，十三位分析師對 Zimmer Biomet Holdings（紐約證券交易所代碼：ZBH）進行了評級，顯示出看漲和看跌情緒的混合。12 個月的平均目標價為 101.08 美元，比之前的估計下降了 3.94%。主要分析師調整了他們的評級，有些下調了目標價，有些則上調了。該公司的市值低於行業平均水平，但顯示出強勁的盈利能力，淨利潤率為 11.54%。然而，其股本回報率和資產回報率低於行業基準，表明在資本效率方面可能面臨挑戰。Zimmer Biomet 專注於骨科重建植入物和外科設備</p>

<p>Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Zimmer Biomet Holdings (NYSE: ZBH) in the last three months.</p>
<div class="lb-trans"><p>在過去三個月中，13 位分析師對 Zimmer Biomet Holdings（紐約證券交易所代碼：ZBH）發佈了從看漲到看跌的多樣化評級。</p>
</div><p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表提供了他們最近評級的簡要概覽，展示了過去 30 天情緒的變化，並與前幾個月進行了比較。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">2</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">2</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
</div><p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $101.08, a high estimate of $120.00, and a low estimate of $86.00. A decline of 3.94% from the prior average price target is evident in the current average.</p>
<div class="lb-trans"><p>分析師通過對 12 個月價格目標的評估提供了更深入的見解，揭示了平均目標為 101.08 美元，最高預估為 120.00 美元，最低預估為 86.00 美元。目前的平均價格目標較之前的平均價格目標下降了 3.94%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769626848_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1769626848_0.png"/></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<div class="lb-trans"><h2>理解分析師評級：全面解析</h2>
</div><p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Zimmer Biomet Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>對近期分析師行動的深入分析揭示了金融專家對 Zimmer Biomet Holdings 的看法。以下總結概述了關鍵分析師、他們的最新評估以及對評級和價格目標的調整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Lowers</td>
<td>Sell</td>
<td>$86.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$99.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Maintains</td>
<td>Buy</td>
<td>$112.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$94.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Caitlin Roberts</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$93.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Lowers</td>
<td>Sell</td>
<td>$88.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$101.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$104.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$105.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$112.00</td>
<td>$122.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>下調</td>
<td>賣出</td>
<td>$86.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>上調</td>
<td>市場表現</td>
<td>$99.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>維持</td>
<td>買入</td>
<td>$112.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>上調</td>
<td>超越市場</td>
<td>$120.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>下調</td>
<td>中性</td>
<td>$100.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>下調</td>
<td>中性</td>
<td>$94.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Caitlin Roberts</td>
<td>Canaccord Genuity</td>
<td>下調</td>
<td>持有</td>
<td>$93.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>下調</td>
<td>賣出</td>
<td>$88.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>下調</td>
<td>超越市場</td>
<td>$101.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>下調</td>
<td>低配</td>
<td>$104.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>下調</td>
<td>中性</td>
<td>$100.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>下調</td>
<td>低配</td>
<td>$105.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>下調</td>
<td>買入</td>
<td>$112.00</td>
<td>$122.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>關鍵見解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Zimmer Biomet Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Zimmer Biomet Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>採取的行動：</strong> 分析師根據市場動態和公司表現更新他們的建議。無論是'維持'、'上調'還是'下調'，都表明他們對 Zimmer Biomet Holdings 近期發展的反應。這為分析師對公司當前狀態的看法提供了見解。</li>
<li><strong>評級：</strong> 分析師提供的定性見解揭示了股票表現，從'超越市場'到'低於市場'。這些評級傳達了對 Zimmer Biomet Holdings 相對於更廣泛市場的表現預期。</li>
<li><strong>價格目標：</strong> 分析師設定價格目標作為對股票未來價值的估計。比較當前和之前的價格目標提供了分析師預期隨時間變化的見解。這些信息對尋求瞭解股票潛在未來表現的投資者來説非常有價值。</li>
</ul>
</div><p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Zimmer Biomet Holdings's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<div class="lb-trans"><p>將這些分析師評估與相關財務指標結合分析，可以全面瞭解 Zimmer Biomet Holdings 的市場地位。保持信息靈通，並在我們的評級表的幫助下做出數據驅動的決策。</p>
</div><p>Stay up to date on Zimmer Biomet Holdings analyst ratings.</p>
<div class="lb-trans"><p>隨時瞭解 Zimmer Biomet Holdings 的分析師評級。</p>
</div><h2>Discovering Zimmer Biomet Holdings: A Closer Look</h2>
<div class="lb-trans"><h2>發現 Zimmer Biomet Holdings：更深入的瞭解</h2>
</div><p>Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.</p>
<div class="lb-trans"><p>Zimmer Biomet 設計、製造和銷售骨科重建植入物，以及骨科手術所需的供應和手術設備。通過在 2003 年收購 Centerpulse 和在 2015 年收購 Biomet，Zimmer 在美國、歐洲和日本的重建市場中佔據領先份額。大約三分之二的總收入來自大型關節的銷售；另外四分之一來自四肢、創傷、運動醫學和相關手術產品。該公司於 2022 年剝離了其牙科和脊柱業務。</p>
</div><h3>Zimmer Biomet Holdings: Delving into Financials</h3>
<div class="lb-trans"><h3>Zimmer Biomet Holdings：深入財務分析</h3>
</div><p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<div class="lb-trans"><p><strong>市值視角：</strong> 該公司的市值低於行業平均水平，表明其相較於同行規模較小。這種定位可能受到感知增長潛力或運營規模等因素的影響。</p>
</div><p><strong>Revenue Growth:</strong> Zimmer Biomet Holdings displayed positive results in 3M. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately <strong>9.71%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<div class="lb-trans"><p><strong>收入增長：</strong> Zimmer Biomet Holdings 在 2023 年第三季度表現出積極的結果。截至 2025 年 9 月 30 日，該公司實現了約 <strong>9.71%</strong> 的穩健收入增長率。這表明公司的營業收入顯著增加。與行業同行相比，該公司的增長率低於醫療保健行業的平均水平。</p>
</div><p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>11.54%,</strong> the company showcases strong profitability and effective cost control.</p>
<div class="lb-trans"><p><strong>淨利潤率：</strong> 該公司的淨利潤率表現突出，超過行業平均水平。憑藉 <strong>11.54%</strong> 的淨利潤率，該公司展示了強大的盈利能力和有效的成本控制。</p>
</div><p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>1.83%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<div class="lb-trans"><p><strong>股本回報率（ROE）：</strong> 該公司的 ROE 低於行業基準，表明在有效利用股本方面可能存在困難。ROE 為 <strong>1.83%</strong>，公司可能需要解決為股東創造滿意回報的挑戰。</p>
</div><p><strong>Return on Assets (ROA):</strong> Zimmer Biomet Holdings's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>1.0%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<div class="lb-trans"><p><strong>資產回報率（ROA）：</strong> Zimmer Biomet Holdings 的 ROA 低於行業標準，表明在有效利用資產方面可能存在困難。ROA 為 <strong>1.0%</strong>，公司可能面臨從其資產中提供滿意回報的挑戰。</p>
</div><p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.64</strong>, Zimmer Biomet Holdings adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<div class="lb-trans"><p><strong>債務管理：</strong> Zimmer Biomet Holdings 的債務與股本比率低於平均水平，為 <strong>0.64</strong>，採取了謹慎的財務策略，表明其在債務管理方面採取了平衡的方法。</p>
</div><h2>The Basics of Analyst Ratings</h2>
<div class="lb-trans"><h2>分析師評級基礎知識</h2>
</div><p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<div class="lb-trans"><p>Benzinga 跟蹤 150 家分析師公司並報告它們的股票預期。分析師通常通過預測公司未來的盈利能力，通常是接下來的五年，以及該公司的收入來源的風險性或可預測性，來得出結論。</p>
</div><p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<div class="lb-trans"><p>分析師參加公司電話會議和會議，研究公司財務報表，並與內部人士溝通，以發佈他們對股票的評級。分析師通常每季度對每隻股票進行一次評級，或者在公司有重大更新時進行評級。</p>
</div><p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<div class="lb-trans"><p>一些分析師發佈他們對增長預期、收益和收入等指標的預測，以提供額外的評級指導。在使用分析師評級時，重要的是要記住，股票和行業分析師也是人，他們只是向投資者提供自己的意見。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</p>
</div>

專家展望：13 位分析師眼中的 Zimmer Biomet Holdings